Scientific knowledge about the brain is finally catching up with our
present lack of a creditable depression management protocol. I have
always been dismissive of what has been done by this crowd to date
for exactly this reasom and the sheer weight of unsupportive evidence
to say nothing of the more bogus claims.
Now we demonstrate that serotonin has zip to do with depression and
that means the meds have operated completely through the placebo
effect.
I do think that the first thing to tackle is the dietary regime.
There a number of imbalances are reflected in the development of
depression and I think that with the exception of clinical depression
that dietary fixes can resolve thev problem. That is still tricky
but it is a far better starting point.
Clinical depression it a biolgical response to something to do with
brain chemistry itself and this needs to be investigated. At least
we now know it is not serotonin. It may be melatonin but that is
just a guess so far.
What If Everything
We Know About Treating Depression Is Wrong?
September 4, 2014
Cliff Weathers,
AlterNet
Scientific studies
indicate that current medications target the wrong parts of the
brain.
A new study is challenging the relationship between depression and an imbalance of serotonin levels in the brain, and brings into doubt how depression has been treated in the U.S. over the past 20 years.
Researchers at the
John D. Dingell VA Medical Center and Wayne State University
School of Medicine in Detroit have bred mice who cannot produce
serotonin in their brains, which should theoretically make them
chronically depressed. But researchers instead found that the
mice showed no signs of depression, but instead acted
aggressively and exhibited compulsive personality traits.
This study backs
recent research indicating that selective serotonin reuptake
inhibitors, or SSRIs, may not be effective in lifting people out of
depression. These commonly used antidepressants such as Prozac,
Paxil, Celexa, Zoloft, and Lexapro, are taken by some 10% of the U.S.
population and nearly 25% of women between 40 and 60 years of age.
More than 350 million people suffer from depression, according to the
World Health Organization, and it is the leading cause of disability
across the globe.
The study was
published in the journal ACS Chemical Neuroscience. Donald Kuhn, the
lead author of the study, set out to find what role, if any,
serotonin played in depression. To do this, Kuhn and his associates
bred mice who lacked the ability to produce serotonin in their
brains, and ran a battery of behavioral tests on them. In
addition to being compulsive and extremely aggressive, the mice who
could not produce serotonin showed no signs of depression-like
symptoms. The researchers also found, to their surprise,
that under stressful conditions, the serotonin-deficient mice behaved
normally.
A subset of the mice
who couldn’t produce serotonin were given antidepressant
medications and they responded in a similar manner to the drugs as
did normal mice. Altogether, the study found that serotonin
is not a major player in depression, and science should
look elsewhere to identify other factors that might be involved.
These results could greatly reshape depression research, the authors
say, and shift the focus of the search for depression treatments.
The study joins others
in directly challenging the notion that depression is related to
lower levels of serotonin in the brain. One study has shown that some
two-thirds of those who take SSRIs remain depressed, while another
study has even found them clinically insignificant.
Critics of common
antidepressants claim they’re not much better than a placebo, yet
may still have unwanted side effects.
SSRIs started to
become widely used in the 1980s. Their introduction was heralded by
the psychiatric community as a new era where safer drugs that
directly targeted the causes of depression would become the standard.
While SSRIs aren’t more effective than the older antidepressants,
such as tricyclics and monoamine oxidase inhibitors,
they are less toxic.
An earlier study by
the National Institute of Mental Health found that two out of three
patients with depression don’t fully recover using modern
antidepressants.
These results “are
important because previously it was unclear just how effective (or
ineffective) antidepressant medications are in patients seeking
treatment in real-world settings,” said James Murrough, a research
fellow at the Mount Sinai School of Medicine Mood and Anxiety
Disorders Program.
About the Author
Cliff Weathers is a
senior editor at AlterNet, covering environmental and consumer
issues. He is a former deputy editor at Consumer Reports. His work
has also appeared in Salon, Car and Driver, Playboy, and Detroit
Monthly among other publications. Follow him on
Twitter @cliffweathers and on Facebook.
No comments:
Post a Comment